Doxorubicin and Dose-Escalated Cyclophosphamide with Granulocyte Colony-Stimulating Factor for the Treatment of Hormone-Resistant Prostate Cancer

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1617-1625

  Small, Eric J ^a,b   Srinivas, Sandy ^a   Egan, Barbara ^a   McMillan, Alex ^a   Rearden, Timothy P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; HUMAN; MALE; NEUTROPENIA; ORCHIECTOMY; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0029923406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1617     Document Type: Article

References (35)

1. Boring CC, Squires TS, Tong T, et al: Cancer statistics, 1994. CA 44:7-26, 1994
2. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:419-424, 1989
3. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemoptherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
4. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? Proc Am Soc Clin Oncol 12:234, 1985 (abstr)
5. Torti FM, Aston D, Lum B, et al: Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1:477-482, 1983
6. Scher H, Yagoda A, Serber M, et al: Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131:1099-1102, 1984
7. Logothetis CJ, Dexeus F, Chong CDK, et al: Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer, in Johnson DE, Logothetis CJ, von Eschenbach AC (eds): Systemic Therapy for Genitourinary Cancer. Chicago, IL, Year Book Medical, 1989, pp 234-238
8. Sternberg CN: Hormone refractory metastatic prostate cancer. Ann Oncol 3:331-335, 1992
9. Saxman S, Ansarai R, Drasga R, et al: Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer 70:2488-2492, 1992
10. Muss HB, Howard V, Richards P II, et al: Cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer: A randomized trial. Cancer 47:1949-1953, 1981
11. Loening SA, Scott WW, deKernion J, et al: A comparison of hydroxyurea, methyl-chloreoethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 125:812-816, 1981
12. Schmidt JD, Scott WW, Gibbons RP, et al: Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121:185-189, 1979
13. Scott WW, Gibbons RP, Johnson DE, et al: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116:211-213, 1976
14. Abell FL, Wilkes JD, Divers L, et al: Oral cyclophosphamide for hormone refractory prostate cancer. Proc Am Soc Clin Oncol 14:243, 1995 (abstr)
15. Ihde DC, Bunn PA, Cohen MH, et al: Effective treatment of hormonally unresponsive metastatic carcinoma of the prostate with Adriamycin and cyclophosphamide. Cancer 45:1300-1310, 1980
16. Stephens RL, Vaughn C, Lane M, et al: Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer, 53:406-410, 1984
17. Izbicki RM, Amer MH, Al-Sarraf M: Combination of Adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: A phase II study. Cancer Treat Rep 63:999-1001, 1979
18. Lloyd RE, Jones SE, Salmon SE, et al: Combination chemotherapy with Adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: A phase II trial. Cancer Treat Rep 60:77-83, 1976
19. Myers C, Cooper M, Stein C: Suramin: A novel growth factor antagonist with activity in hormone-refractory prostate cancer. J Clin Oncol 10:881-889, 1992
20. Eisenberger MA, Reyno LM, Jodrell DI: Suramin, an active drug for prostate cancer: Interim observations in a phase 1 trial. J Natl Cancer Inst 85:611-621, 1993
21. Sella A, Kilbourn R, Amato R, et al: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683-688, 1994
22. Hudes GR, Greenberg R, Krigel RL: Phase II study of estramustine and vinblastine, 2 microtubule inhibitors in hormone-refractory prostate cancer. J Clin Oncol 10:1754-61, 1992
23. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
24. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
25. Hudes G, Nathan F, Chapman A, et al: Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone refractory disease. Proc Am Soc Clin Oncol 14:237, 1995 (abstr)
26. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
27. Figg WD, Sartor O, Cooper MR, et al: Prostate specific antigen decline following discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414, 1995
28. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 76:1428-1434, 1995
29. von Roemeling R, Fisher HAG, Horton J: Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: A phase I/II pilot study. Proc Am Soc Clin Oncol 11:213, 1992 (abstr)
30. Brandes LJ, Bracken SP, Ramsey EW: N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine in combination with cyclophosphamide: An active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 13:1398-1403, 1995
31. Kelly WK, Scher HI, Mazumdar M: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
32. Scher HI, Curley T, Geller N, et al: Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1838, 1990
33. Sridhara R, Eisenberger M, Sinibaldi V, et al: Evaluation of prostate specific antigen as a surrogate marker for response of hromone refractory prostate cancer to suramin therapy. Proc Am Soc Clin Oncol 14:85, 1995 (abstr)
34. Knox SJ, Fowler S, Marquez C, et al: Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 28:445-450, 1994
35. Mac Manus MP, Clarke J, McCormick D, et al: Use of recombinant granulocyte-colony stimulating factor to treat neutropenia occurring during craniospinal irradiation. Int J Radiat Oncol Biol Phys 26:845-850, 1993